Company Profile

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.

Employees

Sector

Pharmaceuticals

More about the company

24-04-19	European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	MT
23-05-02	CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	CI

24-04-19	European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	MT
23-05-02	CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	CI
22-12-14	Court Cancels Public Shares of Vifor Pharma after Merger with CSL	MT
22-11-02	Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	MT
22-10-16	Australia's CSL raises annual profit forecast on Swiss acquisition	RE
22-10-12	Global markets live: Darktrace, Intel, Twitter, Meta, Uber...
22-10-12	Vifor Pharma Gets Approval To Delist From Swiss Bourse	MT
22-09-27	Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	MT
22-08-25	Fitch Pulls Vifor Pharma's Rating After CSL Takeover	MT
22-08-22	Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	MT
22-08-22	Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	MT
22-08-18	UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	MT
22-08-16	Australia biotech giant CSL reports profit dip, flags cost spiral	RE

21-12-14	Octavian Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
21-12-14	Oddo BHF Lifts Price Target on Vifor Pharma, Downgrades Recommendation to Neutral	MT
21-12-07	AlphaValue/Baader Europe Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
21-11-01	Analyst recommendations: Amazon, AMD, Bank of America, Intel, Boeing...
21-09-20	Analyst recommendations: BHP, Lear, Naked Wines, Teradata, Visteon...

22-12-14	Cancellation of remaining publicly held registered shares of Vifor Pharma AG	BU
22-11-28	Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	BU
22-11-25	Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	BU
22-10-20	Approval of extension of exemptions from SIX disclosure and publicity obligations	BU
22-10-12	Approval of delisting of Vifor Pharma AG's registered shares	BU

24-07-22	EU-Kommission verpflichtet Pharmakonzern Vifor zu Gegendarstellung
22-12-14	Vifor: l'action déclarée nulle, décotation le 23 décembre
22-12-14	Vifor-Aktien werden am 23. Dezember dekotiert
22-11-28	CSL Vifor et Fresenius obtiennent le feu vert en Chine pour Ferinject
22-10-20	Vifor toujours exempté de certaines obligations de publier

Galenica AG Stock Monde

Stocks

CH0015536466

Pharmaceuticals

Latest news : Galenica AG

Analysts' recommendations: Galenica AG

Press Releases: Galenica AG

News in other languages: Galenica AG

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-2.39%	-0.47%	+68.30%	+116.05%	1,052B
JOHNSON & JOHNSON	-0.66%	+0.43%	+47.39%	+51.02%	627B
ABBVIE INC.	-0.54%	+1.39%	+20.69%	+64.61%	441B
ROCHE HOLDING AG	+0.28%	-4.64%	+38.98%	+37.93%	349B
NOVARTIS AG	+0.30%	-3.11%	+22.59%	+36.72%	287B
ASTRAZENECA PLC	+0.88%	-3.57%	-1.50%	+7.13%	241B
AMGEN INC.	-0.63%	+1.04%	+40.05%	+56.67%	224B
NOVO NORDISK A/S	-0.81%	-4.39%	-15.77%	-54.08%	202B
GILEAD SCIENCES, INC.	+0.16%	+3.87%	+16.89%	+77.38%	172B
Average	-0.07%	-0.77%	+26.40%	+43.72%	399.46B
Weighted average by Cap.	-0.03%	-0.63%	+38.70%	+62.07%

End-of-day quote Monde
- ^EUR	-